Pacer Advisors’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.7M | Buy |
207,121
+201,519
| +3,597% | +$13.1M | 0.03% | 418 |
|
|
2025
Q4 | $449K | Sell |
5,602
-748
| -12% | -$50.3K | ﹤0.01% | 1811 |
|
|
2025
Q3 | $309K | Buy |
+6,350
| New | +$393K | ﹤0.01% | 1827 |
|
|
2025
Q2 | – | Sell |
-3,011
| Closed | -$191K | – | 3492 |
|
|
2025
Q1 | $191K | Sell |
3,011
-7,093
| -70% | -$482K | ﹤0.01% | 1778 |
|
|
2024
Q4 | $789K | Buy |
10,104
+2,680
| +36% | +$215K | ﹤0.01% | 1460 |
|
|
2024
Q3 | $597K | Sell |
7,424
-234
| -3% | -$18.9K | ﹤0.01% | 1580 |
|
|
2024
Q2 | $634K | Buy |
7,658
+96
| +1% | +$8.45K | ﹤0.01% | 1494 |
|
|
2024
Q1 | $645K | Sell |
7,562
-1,536
| -17% | -$121K | ﹤0.01% | 1444 |
|
|
2023
Q4 | $778K | Buy |
9,098
+3,579
| +65% | +$309K | ﹤0.01% | 1330 |
|
|
2023
Q3 | $494K | Sell |
5,519
-5,080
| -48% | -$454K | ﹤0.01% | 1127 |
|
|
2023
Q2 | $902K | Buy |
+10,599
| New | +$896K | ﹤0.01% | 1176 |
|
|
2023
Q1 | – | Sell |
-9,695
| Closed | -$763K | – | 2272 |
|
|
2022
Q4 | $763K | Buy |
9,695
+7,581
| +359% | +$609K | ﹤0.01% | 995 |
|
|
2022
Q3 | $156K | Buy |
+2,114
| New | +$152K | ﹤0.01% | 1751 |
|
|
2022
Q2 | – | Sell |
-4,420
| Closed | -$279K | – | 2405 |
|
|
2022
Q1 | $279K | Sell |
4,420
-879
| -17% | -$47.8K | ﹤0.01% | 2002 |
|
|
2021
Q4 | $281K | Buy |
5,299
+63
| +1% | +$3.84K | ﹤0.01% | 2010 |
|
|
2021
Q3 | $370K | Sell |
5,236
-1,976
| -27% | -$125K | ﹤0.01% | 1219 |
|
|
2021
Q2 | $481K | Buy |
7,212
+1,787
| +33% | +$126K | 0.01% | 1152 |
|
|
2021
Q1 | $602K | Sell |
5,425
-204
| -4% | -$25.2K | 0.01% | 978 |
|
|
2020
Q4 | $668K | Sell |
5,629
-6,553
| -54% | -$705K | 0.01% | 856 |
|
|
2020
Q3 | $1.06M | Buy |
+12,182
| New | +$1.06M | 0.02% | 675 |
|
|
2020
Q1 | – | Sell |
-17,218
| Closed | -$1.98M | – | 858 |
|
|
2019
Q4 | $1.98M | Sell |
17,218
-1,613
| -9% | -$195K | 0.09% | 266 |
|
|
2019
Q3 | $2.38M | Sell |
18,831
-1,462
| -7% | -$186K | 0.05% | 410 |
|
|
2019
Q2 | $2.44M | Buy |
+20,293
| New | +$2M | 0.06% | 384 |
|
|
2018
Q4 | – | Sell |
-18,532
| Closed | -$2.12M | – | 751 |
|
|
2018
Q3 | $2.12M | Buy |
18,532
+2,022
| +12% | +$209K | 0.08% | 310 |
|
|
2018
Q2 | $1.48M | Buy |
+16,510
| New | +$1.39M | 0.07% | 414 |
|
Other funds holding HAE
VPM
VCM
RRAM
Pacer Advisors's HAE Position: Q1 2026 in Review
Pacer Advisors increased its Haemonetics (HAE) stake by 3,597% in Q1 2026, buying an estimated $13.1M and bringing the position to 207,121 shares worth $11.7M. The position accounts for 0.03% of the portfolio, ranked #418.
Pacer Advisors first reported a position in HAE in Q2 2018 and has held it in 25 quarters since. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- Pacer Advisors held 207,121 shares of Haemonetics worth $11.7M as of Q1 2026.
- Pacer Advisors bought 201,519 Haemonetics shares in Q1 2026, an estimated $13.1M.
- Haemonetics made up 0.03% of Pacer Advisors's portfolio in Q1 2026, its #418 holding.
- Pacer Advisors first reported a position in Haemonetics in Q2 2018 and has held it in 25 quarters since.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.